Pharming Group (NASDAQ:PHAR – Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $8.96, but opened at $8.38. Pharming Group shares last traded at $8.38, with a volume of 364 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday.
Check Out Our Latest Analysis on Pharming Group
Pharming Group Stock Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the business posted $0.02 earnings per share. As a group, research analysts anticipate that Pharming Group will post -0.15 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- How to Calculate Return on Investment (ROI)
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the FTSE 100 index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.